

IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF WEST VIRGINIA

---

NOVO NORDISK INC. and NOVO NORDISK A/S

*Plaintiffs,*

v.

MYLAN PHARMACEUTICALS INC.

*Defendant.*

---

Civil Action No. 1:22-cv-00023

**SUPPLEMENTAL INFORMATION FOR PATENT CASES  
INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA)**

Plaintiffs hereby provide the information below with respect to the deadlines set forth in  
21 U.S.C. 355(j):

Date Patentee(s) Received Notice: February 7, 2022

Date of Expiration of Patent: See Below\*

Thirty Month Stay Deadline: June 5, 2025\*\*

\* U.S. Patent No. 8,114,833 expires on 8/13/2025; U.S. Patent No. 8,684,969 expires on 10/20/2025; U.S. Patent Nos. 9,108,002, 9,616,180, 9,861,757, 10,357,616 and 10,376,652 expire on 1/20/2026; U.S. Patent No. 8,536,122 expires on 3/20/2026; Patent No. RE46,363 expires on 8/3/2026; U.S. Patent No. 9,687,611 expires on 2/27/2027; U.S. Patent Nos. 8,920,383, 9,775,953, 10,220,155, and 11,097,063 expire on 7/17/2026; U.S. Patent No. 9,457,154 expires on 9/27/2027; U.S. Patent No. 9,132,239 expires on 2/1/2032; U.S. Patent No. 8,129,343 expires on 12/5/2031; U.S. Patent No. 10,335,462 expires on 6/21/2033.

\*\* Under 21 C.F.R. Section 314.107(b)(3)(i)(B), the regulatory stay extends until the expiration of 7.5 years from the date of approval of the NDA, rather than 30 months.

DATED: March 18, 2022

Respectfully submitted,

SCHRADER COMPANION DUFF & LAW, PLLC

OF COUNSEL:

Jeffrey J. Oelke  
Ryan P. Johnson  
Robert E. Counihan  
Laura T. Moran  
FENWICK & WEST LLP  
902 Broadway, Suite 14  
New York, NY 10010-6035  
(212) 430-2600

/s/ James F. Companion

James F. Companion (#790)  
Sandra K. Law, Esq. (#6071)  
401 Main Street  
Wheeling, WV 26003  
(304) 233-3390  
jfc@schraderlaw.com  
skl@schraderlaw.com

*Counsel for Plaintiffs*